and led by scientists from John Hopkins Medicine discovered that two doses of psilocybin and supportive psychotherapy resulted in fast, major antidepressant effects.This Viewpoint examines how US states are reforming laws to allow access to psychedelics for therapeutic use, but federal legal guidelines consider these agents being Program I drugs, a